HLA-A and cancer: Owing to the high prevalence of KRASG12V expression across cancers and HLA-A*11:01 allele frequencies in selected populations (14% in US Caucasians and 23% in Asian-Americans)24 this TCR can potentially be used as off-the-shelf reagent to treat thousands of relevant cancer patients per year.